[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-369569-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-369569-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","peptide-based-vesicles-for-cancer-immunotherapy-design-construction-and-applications-mini-review","Peptide based vesicles for cancer immunotherapy: design, construction and applications - Mini review","","Cancer immunotherapy strengthens the innate immune system but is limited by modest efficacy in only subsets of patients and by immune-related adverse events. Cancer vaccines targeting neoantigens can directly amplify anti-tumor immunity and have shown encouraging preclinical and clinical performance across vaccine modalities. This mini review focuses on peptide-based vesicles, describing their basic features, classification, and biological applications, and summarizes design and construction strategies. It further discusses their use across cancer types and highlights key obstacles for clinical translation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/peptide-based-vesicles-for-cancer-immunotherapy-design-construction-and-applications-mini-review/369569/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/peptide-based-vesicles-for-cancer-immunotherapy-design-construction-and-applications-mini-review/369569.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What problems does current cancer immunotherapy face?","Question",{"text":63,"@type":64},"It often shows limited efficacy to only small patient subsets and can cause serious immune-related adverse events.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are peptide-based vaccines of interest?",{"text":68,"@type":64},"They can target neoantigens to direct and amplify immune responses against tumors, with demonstrated efficacy and safety in preclinical and clinical research.",{"name":70,"@type":61,"acceptedAnswer":71},"What advantages do peptide-based vesicles provide in cancer therapy?",{"text":72,"@type":64},"They enhance tumor targeting via functional peptides, offer strong biocompatibility and immune regulation, can help modulate therapeutic drug monitoring-related effects, and are designed to degrade after delivery to reduce long-term toxicity.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},369569,1790247111,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":123,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":144,"preview_page_count":33,"preview_urls":145},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","TYPE Mini Review  \nPUBLISHED 27 May 2025  \nDOI 10.3389/fimmu.2025.1609162  \nOPEN ACCESS  \nEDITED BY  \nYufen Xiao,  \nUniversity of Texas Southwestern Medical Center, United States  \nREVIEWED BY  \nZexiang Chen,  \nUniversity of Texas Southwestern Medical Center, United States  \n*CORRESPONDENCE  \nDongyuan Wang  \n [wangdy2019@hust.edu.cn](wangdy2019@hust.edu.cn)[ ](wangdy2019@hust.edu.cn)Chen Shi  \n[whxhchen@163.com](whxhchen@163.com)  \n†These authors have contributed equally to this work  \nRECEIVED 10 April 2025  \nACCEPTED 08 May 2025  \nPUBLISHED 27 May 2025  \nCITATION  \nYu Y, Lyu J, Muhadaisi Y, Shi C and Wang D (2025) Peptide based vesicles for cancer immunotherapy: design, construction and applications.  \nFront. Immunol. 16:1609162 .  \ndoi: 10.3389/fimmu.2025.1609162  \nCOPYRIGHT  \n© 2025 Yu, Lyu, Muhadaisi, Shi and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nPeptide based vesicles for cancer immunotherapy: design, construction and applications  \nYulin Yu 1,2†, Jiaxin Lyu 3†, Yizimujiang Muhadaisi 3, Chen Shi 1,2* and Dongyuan Wang 1,2*  \n1 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, 2 Hubei Province Clinical Research Center for Precision Medicine for Critical Illness, Wuhan, China, 3School of Pharmacy, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China  \nCancer immunotherapy has emerged as a powerful strategy for clinical treatment of malignant cancers. Despite the advances, cancer immunotherapy has met several challenges such as the limited efﬁcacy to small subsets of patients, and serious autoimmune side effects. Cancer vaccines that target neoantigens to direct and amplify immune responses against tumors, have shown their efﬁcacy and safety in preclinical and clinical researches. The developed cancer vaccines mainly contained peptide vaccines, mRNA vaccine, cell vaccine and oncolytic virus vaccine. In the last decade, both peptide based vaccines and vesicle based vaccines have attracted enormous attention for personalized vaccine development due to their potent efﬁcacy in different tumor models. Peptide based vesicles are one kind of vesicles that are modiﬁed with functional peptides to enhance the efﬁciency of immune response and anti-cancer effect. In this review, we will introduce the basic characteristics, classiﬁcation and biological application of vesicles or peptide based cancer vaccines respectively. Then the design and construction of peptide based vesicles will be summarized. Finally, we concluded the biological applications of peptide based vesicles in various cancer types and analyzed the key obstacles to overcome for their clinical applications. We hope this review could provide a better understanding of the construction of peptide based vesicles and their prospects for clinical applications.  \nKEYWORDS  \ncancer immunotherapy, peptide vaccine, vesicle, peptide based vesicle, anticancer peptide  \n1 Introduction  \nImmunotherapy aims to enhance the natural immune system to eliminate malignant cells. The advent of cancer immunotherapy has a profound impact on the ﬁeld of cancer treatment, signiﬁcantly prolonging the survival of patients with malignant tumors and improving their quality of life (1) . However, few patients can beneﬁt from the currently available immunotherapies and many patients suffer from serious immune-related adverse events (2).  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nIn recent years, various forms of immunotherapy showed great potential for cancer immun","cbCaiq90l0JMX2ao","https://ap.wps.com/l/cbCaiq90l0JMX2ao","pdf",1885841,"English","# Introduction\n## Cancer immunotherapy and vaccine modalities\n## Extracellular vesicles and peptide-based vesicles\n## Design principles and biological applications","[{\"question\":\"What problems does current cancer immunotherapy face?\",\"answer\":\"It often shows limited efficacy to only small patient subsets and can cause serious immune-related adverse events.\"},{\"question\":\"Why are peptide-based vaccines of interest?\",\"answer\":\"They can target neoantigens to direct and amplify immune responses against tumors, with demonstrated efficacy and safety in preclinical and clinical research.\"},{\"question\":\"What advantages do peptide-based vesicles provide in cancer therapy?\",\"answer\":\"They enhance tumor targeting via functional peptides, offer strong biocompatibility and immune regulation, can help modulate therapeutic drug monitoring-related effects, and are designed to degrade after delivery to reduce long-term toxicity.\"}]","Peptide based vesicles for cancer immunotherapy: design, construction and applications - Mini review | PDF",1790183474,25,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ebecfda57ab8017d68a909bafc187054.webp",983,1389,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5e3294e4ba987f9fc3b7bb2f0315d077.webp",982,1388,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/302df514ef997a939246fa35dfbf3d46.webp",981,1386,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/15a2b45c6990ac38f3de86347e2d049e.webp",980,1385]